Le Lézard
Classified in: Health, Science and technology
Subject: PLW

U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent



INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection).

In the inter partes review (IPR) proceedings initiated by Neptune Generics, LLC and Sandoz Inc., the U.S. PTO found that the claims of the vitamin regimen patent are valid. If the patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022, preventing marketing of generic products for as long as the patent remains in force.

"We are pleased with today's ruling by the U.S. PTO finding the claims of the Alimta vitamin regimen patent are valid," said Michael J. Harrington, senior vice president and general counsel for Lilly. "This ruling largely confirms the earlier decision of the district court which was affirmed on appeal by a unanimous court."

Harrington continued, "The significant scientific research that Lilly performed in support of the vitamin regimen patent deserves intellectual property protection, which has been confirmed in every validity challenge to date. We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights help support the development of the next generation of innovative medicines."

In March 2014, the U.S. Court for the Southern District of Indiana upheld the validity of the vitamin regimen patent. In August 2015, the same court ruled in Lilly's favor regarding infringement of the vitamin regimen patent. The U.S. Court of Appeals for the Federal Circuit confirmed these rulings in a unanimous decision in January 2017, finding the patent is valid and would be infringed by the generic challengers' proposed products.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.  C-LLY   

This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any appeal. Also, the company cannot predict whether generic pemetrexed will be marketed prior to the expiration of the vitamin regimen patent. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Alimta® (pemetrexed, Lilly)

Refer to:

Lauren Zierke; lauren_zierke@lilly.com; (317) 989-2853 (Media)   


Phil Johnson; johnson_philip_l@lilly.com; (317) 655-6874 (Investors)

 

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

 

SOURCE Eli Lilly and Company


These press releases may also interest you

at 20:30
SYDNEY, Oct. 23, 2017 /PRNewswire/ -- RubySketch announced today that it has launched a new 3D Home Design & Interior Design DIY software that plugs into SketchUp and will help create more affordable housing by reducing the cost of building and...

at 19:46
SAN JOSE, Calif., Oct. 23, 2017 /PRNewswire/ -- Sanmina Corporation (NASDAQ: SANM) announced today that it will host its fourth quarter and fiscal year 2017 earnings conference call on Monday, October 30, 2017 at 5:00 PM ET.  Mr. Bob Eulau, Chief...

at 19:10
OTTAWA, Oct. 23, 2017 /CNW/ - BluMetric Environmental Inc. (TSXV: BLM), a leading Canadian cleantech company, announced today that the Company has completed the conversion of $122,793 of certain existing debt for 511,638 common shares of the Company,...

at 19:05
AACHEN, Germany and HAAR, Germany and LONDON, October 24, 2017 /PRNewswire/ -- Vodafone ranks second, Three comes in third and O2 ranks last.  P3, the international consulting, engineering and testing services company, has named EE as the leading...

at 18:36
RIO DE JANEIRO, Oct. 23, 2017 /PRNewswire/ -- Oi S.A. ? In Judicial Reorganization ("Oi" or the "Company"), pursuant to Article 157, Paragraph 4, of Law No. 6,404/76 and under CVM Instruction No. 358/02, and in addition to the Material Fact...

at 18:19
SAN JOSE, Calif., Oct. 23, 2017 /PRNewswire/ -- Worldwide provider of advanced IoT wireless modules, Amp'ed RF Wireless Technology announces a new integrated WFV3918 video module designed for streaming HD video via Wi-Fi directly to iOS and Android...




News published on 5 october 2017 at 16:13 and distributed by: